Arthritis News and Research

Latest Arthritis News and Research

Limiting inflammation can control accumulation of carotid atherosclerosis in RA patients

New data presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta show that systemic inflammation and rheumatoid arthritis disease activity may contribute to the progression of atherosclerosis in people with RA. The data also show that this progression may be modified favorably by TNF inhibitors and detrimentally by glucocorticoids.

8 Nov 2010

Study suggests bacterial products contribute to autoimmune diseases

Researchers are using 21st century technologies to investigate the century old hypothesis that certain autoimmune diseases, including rheumatoid arthritis, are caused by bacteria living in the human body and will present their initial data this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Anti-TNF therapies commonly used to treat rheumatoid arthritis have been found to potentially reduce the risk of developing Alzheimer's dementia among people with rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Hydroxychloroquine may reduce cardiac neonatal lupus in subsequent pregnancies: Research

Women with anti-SSA/Ro antibodies and a previous child who has heart block a condition where the electrical signal that makes the heart beat is damaged may potentially decrease their risk of delivering another child with life threatening heart disease by taking hydroxychloroquine (Plaquenil), according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

People with SLE more likely to develop hematologic malignancies

People with systemic lupus erythematosus are 1.15 times as likely to develop cancer as the general population and more than 2.5 times as likely to develop hematologic malignancies, such as lymphoma and leukemia, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Statin drugs do not benefit pediatric lupus patients

Lupus puts children at higher risk for coronary artery disease when they become adults, but routinely using statins doesn't provide enough benefit to warrant their regular use in children and adolescents, according to the largest study of pediatric lupus patients to date.

8 Nov 2010

Amgen wins Scrip Best New Drug award for Prolia

Amgen is pleased to announce that it has won the Best New Drug award for Prolia™ (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the 2010 Scrip Awards ceremony Nov. 4 in London. Named one of TIME's Top 10 Medical Breakthroughs of 2009, Prolia is the first treatment specifically designed to target osteoclasts, the cells that break down bone.

8 Nov 2010

Chronic lower back pain may be linked to axial spondyloarthritis: Research

Chronic lower back pain may be linked to a recently defined form of inflammatory arthritis known as axial spondyloarthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Alder to present data of ALD518 two clinical studies for rheumatoid arthritis at American College Meeting

Alder Biopharmaceuticals Inc. today announced that data from two clinical studies of its ALD518 investigational antibody therapeutic will be presented at the Annual Meeting of the American College of Rheumatology in Atlanta.

8 Nov 2010

Gout and hyperuricemia continue to rise in the U.S.

Gout rates and related cases of hyperuricema have increased over the past two decades, according to research presented at the Nov 2010, American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, together with investigators at the University of Texas Medical Branch (UTMB) and the Division of Vector Borne Diseases (DVBD) of the Centers for Disease Control and Prevention, will make an oral presentation today at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on preclinical results of the Company's experimental chikungunya virus (CHIKV) vaccine.

8 Nov 2010

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

Genentech, Inc., a member of the Roche Group today announced updated data from a Phase III study (ROSE) that showed rheumatoid arthritis (RA) patients receiving ACTEMRA (tocilizumab) experienced a rapid, measured response as early as one week after beginning ACTEMRA, and improvement in disease activity within four weeks.

8 Nov 2010

Genentech announces Phase II RG7204 clinical study results for metastatic melanoma tumors

Genentech, Inc., a member of the Roche Group today announced results from a Phase II clinical study of RG7204 (PLX4032), an investigational first-in-class molecule designed to selectively inhibit a cancer-causing, mutated form of the BRAF protein found in approximately half of metastatic melanoma tumors.

8 Nov 2010

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it was awarded two grants totaling $488,959 under the Qualifying Therapeutic Discovery Project (QTDP) Program to support the Company's Alzheimer's disease and multiple sclerosis programs currently in clinical testing.

4 Nov 2010

Patient share of Actemra for RA to exceed patient share for Cimzia and Simponi, says Report

Bio-Trends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis Q3 2010. This report covers the use of biologics for the treatment of rheumatoid arthritis (RA). The report, part of a quarterly series, focuses on current and future use of biologic agents, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers' patient assistance programs.

4 Nov 2010

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced positive preliminary results of a Phase IIa study in inflammatory bowel disease (IBD) with its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release.

4 Nov 2010

Phase III study suggests CYCLOSET tablets improve glycemic control

Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.

4 Nov 2010

Etanercept plus MTX improves height, weight, and BMI in children with juvenile idiopathic arthritis

Researchers from the Cincinnati Children's Hospital Medical Center observed a statistically significant increase in mean height, weight, and body mass index (BMI) percentiles in patients with juvenile idiopathic arthritis (JIA) who were treated with etanercept or etanercept plus methotrexate (MTX). JIA patients treated with MTX alone did not display an increase in growth percentiles.

4 Nov 2010

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

New primary care models needed to improve care and outcomes for older adults

In an article published in November 3 edition of Journal of the American Medical Association (JAMA), Chad Boult, MD, MPH, MBA, professor of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health, calls for key improvements to primary care in order to improve the health of the nation's most costly patients-older adults with multiple chronic conditions.

3 Nov 2010

Arthritis News and Research

Latest Arthritis News and Research

Limiting inflammation can control accumulation of carotid atherosclerosis in RA patients

Study suggests bacterial products contribute to autoimmune diseases

Anti-TNF therapies may reduce Alzheimer's risk among people with rheumatoid arthritis

Hydroxychloroquine may reduce cardiac neonatal lupus in subsequent pregnancies: Research

People with SLE more likely to develop hematologic malignancies

Statin drugs do not benefit pediatric lupus patients

Amgen wins Scrip Best New Drug award for Prolia

Chronic lower back pain may be linked to axial spondyloarthritis: Research

Alder to present data of ALD518 two clinical studies for rheumatoid arthritis at American College Meeting

Gout and hyperuricemia continue to rise in the U.S.

Inviragen to present data on CHIKV vaccine at ASTMH meeting

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

Genentech announces Phase II RG7204 clinical study results for metastatic melanoma tumors

Adeona receives $488,959 grants under QTDP program to support Alzheimer's, multiple sclerosis programs

Patient share of Actemra for RA to exceed patient share for Cimzia and Simponi, says Report

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

Phase III study suggests CYCLOSET tablets improve glycemic control

Etanercept plus MTX improves height, weight, and BMI in children with juvenile idiopathic arthritis

Bortezomib reduces inflammation and promotes bone healing in arthritis models

New primary care models needed to improve care and outcomes for older adults

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Arthritis News and Research

Latest Arthritis News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in